PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

NCT00538798 | Completed Phase 1

• 2 other identifiers: 07008207-M-0082
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The metabotropic glutamate subtype five (mGluR5) receptor is a protein found in the brain and is the target for the excitatory chemical messenger glutimate. The purpose of this protocol is to measure mGluR5 receptors in the brain using positron emission tomography (PET) and a research drug called \[18F\]SP203.

Conditions

Healthy; Glutamate Receptor; mGlur5 Protein; Excitatory Amino Acid Receptors; Drug Kinetics; PET Scan

Keywords

Pharmacokinetics; Binding Potential; Glutamate; Positron Emission Tomography; Metabolic Glutamate Receptors; Healthy Volunteer; HV

Interventions

[18F]SP203 DRUG

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy control subjects aged 18 65 years, with history/physical exam, ECG, and laboratory tests within one year of the PET scan within normal limits.

You may not qualify if:

• Current psychiatric illness, substance abuse or severe systemic disease based on history and physical exam.
• Laboratory tests with clinically significant abnormalities.
• Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.
• Pregnancy and breast feeding.
• Claustrophobia. (part 1 and 3 only)
• Presence of ferromagnetic metal in the body or heart pacemaker. (part 1 and 3 only)
• Positive HIV test.
• Consumed alcohol within 48 hours before the PET scan.

Sponsors & Collaborators

• National Institute of Mental Health (NIMH): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Brodkin J, Bradbury M, Busse C, Warren N, Bristow LJ, Varney MA. Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur J Neurosci. 2002 Dec;16(11):2241-4. doi: 10.1046/j.1460-9568.2002.02294.x.

  PMID: 12473093 BACKGROUND

• Cosford ND, Roppe J, Tehrani L, Schweiger EJ, Seiders TJ, Chaudary A, Rao S, Varney MA. [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett. 2003 Feb 10;13(3):351-4. doi: 10.1016/s0960-894x(02)00997-6.

  PMID: 12565928 BACKGROUND

• Fujita M, Seibyl JP, Verhoeff NP, Ichise M, Baldwin RM, Zoghbi SS, Burger C, Staley JK, Rajeevan N, Charney DS, Innis RB. Kinetic and equilibrium analyses of [(123)I]epidepride binding to striatal and extrastriatal dopamine D(2) receptors. Synapse. 1999 Dec 15;34(4):290-304. doi: 10.1002/(SICI)1098-2396(19991215)34:43.0.CO;2-B.

  PMID: 10529723 BACKGROUND

Study Officials

• Masahiro Fujita, M.D.

  National Institute of Mental Health (NIMH)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Purpose: TREATMENT
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 2, 2007
• First Posted: October 3, 2007
• Study Start: September 28, 2007
• Study Completion: March 17, 2015
• Last Updated: July 5, 2018

Record last verified: 2015-03-17

Locations

US (1)